Motus GI (MOTS), which operates across the United States and Israel through its subsidiaries, is known for its colorectal cancer detection system Pure-Vu. But let’s find out if the Pure-Vu system is sufficient to deliver healthy returns to the company and its investors in the near-term. Read on.Medical technology company Motus GI Holdings, Inc. (MOTS) provides endoscopy solutions and is known for its flagship product Pure-Vu. The system helps in early detection and prevention of colorectal cancer and other diseases of the rectum and colon. However, the company is still in its early stages of development.
MOTS’ stock has lost 3.5% over the past three months to close Friday’s trading session at $1.39. It is currently trading 49.3% below its $2.74 52-week high and much below its $10.50 all-time high, which it hit on July 1, 2018.
The company had an unimpressive market debut in 2018, and it has failed to generate a profit so far. So, even as the healthcare industry overall is expected to see decent growth this year and beyond, we think it’s wise to avoid MOTS now.